Short Interfering RNA (siRNA) has come of age to unleash its full potential as a potent therapeutic. The onset of a series of FDA approvals of the siRNA medication targeting rare, previously untreatable genetic disorders and several other promising drug candidates in clinical trials have established the RNA Interference (RNAi) technology in the therapeutic realms. Designing a highly effective siRNA is one of the critical challenges of its downstream usage as a potential drug. Continue reading Designing therapeutic siRNAs